Inhibiting Rev-erbα-mediated ferroptosis alleviates susceptibility to myocardial ischemia-reperfusion injury in type 2 diabetes

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

Hong Sun, Pouya Saeedi, Suvi Karuranga et al. · Diabetes Research and Clinical Practice · 2021 · 9.7K citations · Full text

Medicine, Chronic Disease Prevention, Endocrinology +12

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq et al. · Circulation · 2022 · 6K citations · Full text

Medicine, Cardiology, Preventive Medicine +17

Adverse metabolic and cardiovascular consequences of circadian misalignment

Frank A. J. L. Scheer, Michael F. Hilton, Christos S. Mantzoros et al. · Proceedings of the National Academy of Sciences · 2009 · 2.3K citations · Full text

Nursing, Endocrinology, Physiology +17

Insight into the mechanism of ferroptosis inhibition by ferrostatin-1

Giovanni Miotto, Monica Rossetto, Maria Luisa Di Paolo et al. · Redox Biology · 2019 · 884 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists

Laura A. Solt, Yongjun Wang, Subhashis Banerjee et al. · Nature · 2012 · 826 citations · Full text

Life Sciences, Biochemistry, Pharmacology +14